ZBTB32 and neoplasm: This targeted modification increased NSCLC cell‐derived CCL5 secretion via CyPA‐CD147‐p38‐ZBTB32 signaling, which promoted NSCLC immunosuppression via CCL5/CCR5 axis‐dependent tumor cell‐macrophage crosstalk.